Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the efficacy and safety of OPC-249 by once daily
inhalation at 0 (placebo), 30, 60 or 120 IU for 4 weeks in patients with pain due to
osteoporosis.